Personal information

Activities

Collapse all

Employment (3)

AstraZeneca (United Kingdom): Cambridge, GB

2022-09 to present | Associate Director
Employment
Source: Self-asserted source
Marina Natoli

University of Basel: Basel, Basel-Stadt, CH

2022 | Postdoctoral researcher
Employment
Source: Self-asserted source
Marina Natoli

Imperial College London: London, GB

2016-07-04 to 2019 | PhD Candidate (Surgery and Cancer)
Employment
Source: Self-asserted source
Marina Natoli

Education and qualifications (2)

Imperial College London: London, GB

PhD
Education
Source: Self-asserted source
Marina Natoli

University College London: London, London, GB

2013-09-01 to 2014-09-01 | MSc Biomedical Sciences
Education
Source: Self-asserted source
Marina Natoli

Works (10)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors

Journal for ImmunoTherapy of Cancer
2022-11 | Journal article
DOI: 10.1136/jitc-2022-005548
Contributors: Marina Natoli; Klas Hatje; Pratiksha Gulati; Fabian Junker; Petra Herzig; Zhiwen Jiang; Iakov I Davydov; Markus Germann; Marta Trüb; Daniel Marbach et al.
Source: check_circle
Crossref

NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity

Science Translational Medicine
2022-07-13 | Journal article
DOI: 10.1126/scitranslmed.abm9043
Contributors: Nicole Kirchhammer; Marcel P. Trefny; Marina Natoli; Dominik Brücher; Sheena N. Smith; Franziska Werner; Victoria Koch; David Schreiner; Ewelina Bartoszek; Mélanie Buchi et al.
Source: check_circle
Crossref

Adaptive anti-tumor immunity is orchestrated by a population of CCL5-producing tissue-resident NK cells

2021-05-27 | Other
DOI: 10.1101/2021.05.27.445981
Contributors: Nicole Kirchhammer; Marcel P Trefny; Marina Natoli; Dominik Brücher; Sheena N Smith; Franziska Werner; Victoria Koch; David Schreiner; Ewelina Bartoszek; Mélanie Buchi et al.
Source: check_circle
Crossref

Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma

2021-05-11 | Other
DOI: 10.1101/2021.05.09.443282
Contributors: Pavlina Spiliopoulou; Sarah Spear; Hasan Mirza; Ian Garner; Lynn McGarry; Fabio Grundland-Freile; Zhao Cheng; Darren P. Ennis; Sophie McNamara; Marina Natoli et al.
Source: check_circle
Crossref

Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression

Journal for ImmunoTherapy of Cancer
2021-01 | Journal article
DOI: 10.1136/jitc-2020-001519
Contributors: Marina Natoli; John Gallon; Haonan Lu; Ala Amgheib; David J Pinato; Francesco A Mauri; Teresa Marafioti; Ayse U Akarca; Ines Ullmo; Jacey Ip et al.
Source: check_circle
Crossref

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity

Frontiers in oncology
2021-01-01 | Journal article
PMC: PMC7966525
Source: Self-asserted source
Marina Natoli

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Journal for ImmunoTherapy of Cancer
2020-10 | Journal article
DOI: 10.1136/jitc-2020-001222
Contributors: Natalia Rodrigues Mantuano; Marina Natoli; Alfred Zippelius; Heinz Läubli
Source: check_circle
Crossref

Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade

Cancer Immunology, Immunotherapy
2020-08-21 | Journal article
DOI: 10.1007/s00262-020-02544-5
Contributors: Marina Natoli; Nair Bonito; James D. Robinson; Sadaf Ghaem-Maghami; Yumeng Mao
Source: check_circle
Crossref

Correction to: Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade

Cancer Immunology, Immunotherapy
2020-08-18 | Journal article
DOI: 10.1007/s00262-020-02601-z
Contributors: Marina Natoli; Nair Bonito; James D. Robinson; Sadaf Ghaem-Maghami; Yumeng Mao
Source: check_circle
Crossref

Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer

Cancer Immunology, Immunotherapy
2018-11-24 | Journal article
DOI: 10.1007/s00262-018-2199-8
Contributors: John Wahba; Marina Natoli; Lynsey M. Whilding; Ana C. Parente-Pereira; Youngrock Jung; Stefania Zona; Eric W.-F. Lam; J. Richard Smith; John Maher; Sadaf Ghaem-Maghami
Source: check_circle
Crossref
How many people are using ORCID?